Heart failure with preserved ejection fraction (HFpEF) affects half of all patients with heart
failure worldwide, is increasing in prevalence, confers substantial morbidity and mortality …

Heart failure with preserved ejection fraction (HFpEF) accounts for nearly half of all heart
failure cases and has a prevalence that is expected to rise with the growing ageing …

Aims To date, clinical evidence of microvascular dysfunction in patients with heart failure
(HF) with preserved ejection fraction (HFpEF) has been limited. We aimed to investigate the …

The endothelium is considered to be the gatekeeper of the vessel wall, maintaining and
regulating vascular integrity. In patients with chronic kidney disease, protective endothelial …

Chronic heart failure (CHF) is a complex syndrome that results from structural and functional
disturbances that affect the ability of the heart to supply oxygen to tissues. It largely affects …

Over the past 2 decades, the syndrome of heart failure with preserved ejection fraction
(HFpEF) received a lot of attention. 1–19 However, little therapeutic progress was made. 20 …

Heart failure with preserved ejection fraction (HFpEF) has been recognized as the greatest
single unmet need in cardiovascular medicine. Indeed, the morbi-mortality of HFpEF is high …

Endothelial dysfunction is characterized by nitric oxide dysregulation and an altered redox
state. Oxidative stress and inflammatory markers prevail, thus promoting atherogenesis and …

Myocardial ischemia with no obstructive coronary arteries (INOCA) is a chronic coronary
syndrome condition that is increasingly being recognized as a substantial contributor to …

Heart failure (HF) is one of the largest drivers of morbidity and health care expenditure in the
world and continues to increase in prevalence at an alarming rate. Most of this increasing …